Presentation for Earning calls with Analysts/Institutional Investors on Un-Audited Financial Results for the quarter and half year ended September 30, 2026

MedPlus Health Services Limited October 27, 2026 The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Dalal Street, Fort, Bandra Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai – 400 051 BSE Scrip Code: 543427 NSE Symbol: MEDPLUS Dear Sir/ Madam, Sub: Presentation for Earnings Call with Analysts/Institutional Investors on Un-Audited Financial Results for the quarter and half year ended September 30, 2026 Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our letter dated October 17, 2026 please find enclosed herewith the presentation for Earnings Call with Analysts/Institutional Investors on Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 scheduled to be held on Wednesday, October 28, 2026, at 16:00 Hrs. (IST). The same will be available on the website of the Company at www.medplusindia.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively. Thanking You Yours faithfully For MedPlus Health Services Limited Shrenik Soni Company Secretary & Compliance Officer ICSI M. No. F12400 Encl: a/a 040-6724 6724 Regd. off. H. No: 11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad – 500037, Telangana, India CIN No: L85110TG2006PLC051845 I Website: www.medplusindia.com I Email:medplus@medplusindia.com MEDPLUS HEALTH SERVICES LIMITED Q2 FY2027 INVESTOR PRESENTATION October 2026 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by MedPlus Health Services Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. The MedPlus Story e Marked presence of 20 years with network of 5,640+ Stores Spread across O 13 states and 1 union territory Cluster based expansion strategy: ‘Continue 2nd Largest Pharma Retailer in the country deeper penetration vs. with pioneer in omni channel Wider reach’ Well curated SKU’s at Outlets and 31k+ Employees ~51k SKU’s across warehouses Store level Unit economics with ROCE of over 70% Serving the Customers of ~860 Cities ~1,600 Outlets which are < 24M, upon maturity are P&L accretive Q2FY27 2 t a Q2 FY2027 Highlights (1/2) ₹ 20,371m Revenue ₹ 5,108m Gross Margin • ₹ 3,578m increase over Q2FY26 • 25.1% GM%, lower by 110 bps yoy, 21.3% yoy increase by 60 bps qoq • ₹ 1,575m increase over Q1FY27 8.4% qoq • 0.6% decrease in private label over Q2FY26 166 Store Net Additions Stores > 12 months • 13.2% revenue growth over Q2FY26 • 219 gross additions • 11.7% Store Level EBITDA margin • 101 net additions beyond Tier-One • 72.0% Store Level Operating ROCE • 5,642 stores as on 30-Sep-26 ₹ 885m Pharmacy Operating ₹ 370m Operating Cash Flow EBITDA • 37.7% OCF/ Operating EBITDA • 4.4% Operating EBITDA margin in • ₹ 5,439m closing cash, bank balance Pharmacy, increased by 120 bps qoq & investments (including ₹ 818m in • ₹ 981m Company Operating EBITDA investments) Q2FY27 3 t a Q2 FY2027 Highlights (2/2) R Revenue, ₹m Gross Margin Operating EBITDA EBITDA, ₹m 20,371 5.8% 26.1% 26.2% 26.5% 5.3% 5.4% 1,898 1,906 d 18,644 18,796 25.1% 4.8% 1,769 e 18,061 24.5% 1,663 1,531 a 16,793 3.5% l o 1,076 968 981 s 887 o 651 19,935 1,803 1,774 1,688 25.3% 5.6% 1,616 17,715 18,266 18,399 25.0% 25.1% 23.9% 5.1% 5.2% 4.4% 1,426 y 23.3% 16,440 m 3.2% r 1,022 a 925 885 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Operating EBITDA ₹m Operating EBITDA margin Q2FY27 4 t a H1 FY2027 Highlights ₹ 39,167m Revenue ₹ 9,712m Gross Margin • ₹ 6,947m increase over H1FY26 • 24.8% GM%, decreased by 130 bps 21.6% yoy yoy • 0.7% decrease in private label over H1FY26 312 Store Net Additions Stores > 12 months • 14.9% revenue growth over H1FY26 • 441 gross additions • 11.1% Store Level EBITDA margin • 226 net additions beyond Tier-One ₹ 1,473m Pharmacy ₹ 1,622m Operating Cash Flow Operating EBITDA • 99.4% OCF/ Operating EBITDA • 3.8% Operating EBITDA margin in • ₹ 5,439m closing cash, bank balance & Pharmacy (decreased by 100 bps investments (including ₹ 818m in over H1FY26) investments) • ₹ 1,632m Company Operating EBITDA Q2FY27 5 Cluster Based Network Enables Profitable Omni-Channel Service Stores As On Sep-26 Strong Cluster Based Network Strong network of 5,642 stores across Metros, Tier-One, Tier-Two and beyond. 5,642 stores 2- hour delivery Ability to service 100% market – acute + chronic Online only players cannot match this As opposed to online only players that 1 proposition given lack of hyperlocal largely cater to only chronic segment store presence 1 (37%1 of the market) 57 764 193 Lower delivery costs 644 Lower customer acquisition cost Because of the hyperlocal presence of As existing stores act as branding sites MedPlus’ 5,642 stores 1048 1145 46 1. For 2020; Proportion of domestic pharmaceutical market. Technopak Advisors (2021). Pharmacy Retail in India Metro Tier-One 2. Stores in Puducherry and Delhi are not represented in the map above. As on 30-Sep-26 we have 10 stores Powered by Bing © GeoNames, Microsoft, TomTom in Puducherry and 1 store in Delhi Tier-Two Tier-Three+ Q2FY27 6 Scale Allows A Large Private Label Basket: 1750+ SKUs Pharma Over 900 products covering Chronic, Acute, OTC & Other Pharmaceutical products Non-Pharma Over 850 products covering, packaged food, baked goods, dry goods, cleaning products, cosme [Showing first 8,000 characters — download PDF for full document]